125 related articles for article (PubMed ID: 28811561)
1. Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves' disease patients.
Zhang R; Tan J; Wang R; Zhang G; Jia Q; Meng Z; Zhang Y
Sci Rep; 2017 Aug; 7(1):8301. PubMed ID: 28811561
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
4. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease.
Santos RB; Romaldini JH; Ward LS
Thyroid; 2004 Jul; 14(7):525-30. PubMed ID: 15307942
[TBL] [Abstract][Full Text] [Related]
5. Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves' disease.
Osaki Y; Sakurai K; Arihara Z; Hata M; Fukazawa H
Endocr J; 2012; 59(2):173-7. PubMed ID: 22095001
[TBL] [Abstract][Full Text] [Related]
6. [Predictors of the efficacy of radioiodine therapy of Graves' disease in children and adolescents].
Rumyantsev PO; Saenko VA; Dzeytova DS; Trukhin AA; Sheremeta MS; Slashchuk KY; Degtyarev MV; Serzhenko SS; Yasuchenia VS; Zakharova SM; Sirota YI
Probl Endokrinol (Mosk); 2020 Oct; 66(4):68-76. PubMed ID: 33351361
[TBL] [Abstract][Full Text] [Related]
7. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease.
Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP
Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662
[TBL] [Abstract][Full Text] [Related]
8. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the success of radioiodine therapy in patients with Graves' disease.
Šfiligoj D; Gaberšček S; Mekjavič PJ; Pirnat E; Zaletel K
Nucl Med Commun; 2015 Jun; 36(6):560-5. PubMed ID: 25714667
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine treatment for pediatric Graves' disease.
Ma C; Kuang A; Xie J; Liu G
Cochrane Database Syst Rev; 2008 Jul; (3):CD006294. PubMed ID: 18646146
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
12. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
14. Age and gender predict the outcome of treatment for Graves' hyperthyroidism.
Allahabadia A; Daykin J; Holder RL; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2000 Mar; 85(3):1038-42. PubMed ID: 10720036
[TBL] [Abstract][Full Text] [Related]
15. Standardized Uptake Value Using Thyroid Quantitative SPECT/CT for the Diagnosis and Evaluation of Graves' Disease: A Prospective Multicenter Study.
Dong F; Li L; Bian Y; Li G; Han X; Li M; Liu J; Xue Y; Li Y; Hu Y; Tan J
Biomed Res Int; 2019; 2019():7589853. PubMed ID: 30834273
[TBL] [Abstract][Full Text] [Related]
16. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
Sawicka N; Sowiński J
Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
[TBL] [Abstract][Full Text] [Related]
17. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
18. Accuracy considerations when using early (four- or six-hour) radioactive iodine uptake to predict twenty-four-hour values for radioactive iodine dosage in the treatment of Graves' disease.
Morris LF; Waxman AD; Braunstein GD
Thyroid; 2000 Sep; 10(9):779-87. PubMed ID: 11041455
[TBL] [Abstract][Full Text] [Related]
19. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography.
Boerner AR; Voth E; Theissen P; Wienhard K; Wagner R; Schicha H
Thyroid; 1998 Sep; 8(9):765-72. PubMed ID: 9777746
[TBL] [Abstract][Full Text] [Related]
20. Analysis of iodine-131-induced early thyroid hormone variations in Graves' disease.
Xu F; Gu A; Pan Y; Yang L; Ma Y
Nucl Med Commun; 2016 Nov; 37(11):1154-9. PubMed ID: 27366942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
